Navigation Links
CareFusion Announces Completion of Exchange Offer for 4.125% Senior Notes Due 2012, 5.125% Senior Notes Due 2014, and 6.375% Senior Notes Due 2019

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- CareFusion Corporation (NYSE: CFN) announced today that it has completed its previously announced offer to exchange (the "Exchange Offer") any and all of its outstanding $250 million aggregate principal amount of 4.125% Senior Notes due 2012, $450 million aggregate principal amount of 5.125% Senior Notes due 2014, and $700 million aggregate principal amount of 6.375% Senior Notes due 2019 (collectively, the "Initial Notes") for new 4.125% Senior Notes due 2012, new 5.125% Senior Notes due 2014, and new 6.375% Senior Notes due 2019 (collectively, the "New Notes") that have been registered under the Securities Act of 1933, as amended (the "Securities Act").

The Exchange Offer was made pursuant to a Registration Rights Agreement entered into by CareFusion when it originally issued the Initial Notes on July 21, 2009. As CareFusion issued the $1.4 billion aggregate principal amount of Initial Notes in a private placement transaction, the Initial Notes were subject to transfer restrictions. The purpose of the Exchange Offer was to allow holders of the Initial Notes to exchange their notes for New Notes that did not have these restrictions. Following the Exchange Offer, CareFusion will continue to have $1.4 billion aggregate principal amount of notes outstanding.

The terms of the New Notes issued in the Exchange Offer are substantially the same as the terms of the Initial Notes, except that the New Notes are registered under the Securities Act, have no transfer restrictions under the federal securities laws, no registration rights, no rights to additional interest and are not subject to the special mandatory redemption feature. All of the Initial Notes were submitted for exchange, and the Company has accepted for exchange all the Initial Notes validly tendered and not withdrawn pursuant to the Exchange Offer.

This announcement does not constitute an offer to purchase or a solicitation of an offer to sell securities. The Exchange Offer was made only pursuant to a prospectus and the related letter of transmittal and only to such persons and in such jurisdictions as is permitted under applicable law.

About CareFusion Corporation

CareFusion (NYSE: CFN) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® IV pumps, Pyxis® automated dispensing and patient identification systems, AVEA® and Pulmonetic Systems ventilators, ChloraPrep®  products, MedMined™ services for infection surveillance, NeuroCare neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 15,000 people across its global operations. More information may be found at

SOURCE CareFusion Corporation



SOURCE CareFusion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. CareFusion Corporation Files Form 10 Registration Statement
2. CareFusion Names Edward Borkowski as Chief Financial Officer
3. CareFusion Announces Board of Directors, Progress on Alaris Consent Decree
4. CareFusion Names Robert Friel to Board of Directors
5. CareFusion Launches New Brand, Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety
6. CareFusion Files Amended Form 10 Registration Statement With SEC
7. CareFusion Corporation Launches International Jazz Festival Series
8. CareFusion to Resume Shipping Alaris(R) Infusion Products
9. Cardinal Health Board of Directors Approves CareFusion Spinoff
10. CareFusion Prices $1.4 Billion of Senior Notes
11. CareFusion Expands Pyxis(R) Perioperative Solutions Offering
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: